Want to see DE:BNN full AI Analyst Report?
BNN Stock Chart & Stats
€2.75
€0.00(0.00%)
At close: 4:00 PM EDT
€2.75
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.05 - €3.89
Previous CloseN/A
Volume3.25K
Average Volume (3M)6.10K
Market Cap
€60.95M
Enterprise Value€116.09
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Jan 14, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding21,847,494
10 Day Avg. Volume11,781
30 Day Avg. Volume6,096
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€52.53M
Bulls Say, Bears Say
Bulls Say
Improving Gross MarginThe improvement in gross margin indicates better economics on the company’s revenue base than in the prior annual periods. If sustained, this could provide greater capacity to cover operating costs and support future profitability, although operating losses remain substantial.
No TTM Debt ReportedReported zero TTM debt reduces current interest and scheduled repayment pressure, giving the company more flexibility than a similarly loss-making business with substantial borrowings. However, prior leverage volatility means this benefit should be viewed as current balance-sheet support rather than a permanent advantage.
Cash Loss Broadly Tracks Accounting LossThe close relationship between free cash flow loss and net income suggests that reported losses are not being amplified by a much larger cash outflow from other operating factors. This offers some transparency in cash conversion, even though the company still consumes cash and remains dependent on funding.
Bears Say
Negative Revenue GrowthDeclining revenue indicates weakening commercial momentum and reduces the operating base available to absorb fixed costs. Unless the trend reverses, lower scale can make it harder to leverage the improved gross margin, fund research activities internally, and move toward sustainable profitability.
Persistent Operating And Net LossesDeep operating and net losses show that the business has not converted revenue into sustainable earnings, despite some gross-margin improvement. Continued losses can consume equity and financial resources, limiting reinvestment capacity and increasing the need for corrective actions or external capital.
Negative Equity And Ongoing Cash BurnNegative shareholders’ equity materially limits loss-absorbing capacity, while negative operating and free cash flow show that the business continues to consume cash. Together, these conditions increase funding and solvency risk and may constrain the company’s ability to absorb further setbacks.
BNN FAQ
What was B.R.A.I.N. Biotechnology Research and Information Network AG’s price range in the past 12 months?
B.R.A.I.N. Biotechnology Research and Information Network AG lowest stock price was €2.05 and its highest was €3.89 in the past 12 months.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap?
B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap is €60.95M.
When is B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date?
B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date is Jan 14, 2027 which is in 120 days.
How were B.R.A.I.N. Biotechnology Research and Information Network AG’s earnings last quarter?
B.R.A.I.N. Biotechnology Research and Information Network AG released its earnings results on Aug 27, 2026. The company reported -€0.163 earnings per share for the quarter.
Is B.R.A.I.N. Biotechnology Research and Information Network AG overvalued?
According to Wall Street analysts B.R.A.I.N. Biotechnology Research and Information Network AG’s price is currently Overvalued.
Does B.R.A.I.N. Biotechnology Research and Information Network AG pay dividends?
B.R.A.I.N. Biotechnology Research and Information Network AG does not currently pay dividends.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate?
B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does B.R.A.I.N. Biotechnology Research and Information Network AG have?
B.R.A.I.N. Biotechnology Research and Information Network AG has 21,847,494 shares outstanding.
What happened to B.R.A.I.N. Biotechnology Research and Information Network AG’s price movement after its last earnings report?
B.R.A.I.N. Biotechnology Research and Information Network AG reported an EPS of -€0.163 in its last earnings report. Following the earnings report the stock price went down -1.786%.
Which hedge fund is a major shareholder of B.R.A.I.N. Biotechnology Research and Information Network AG?
Currently, no hedge funds are holding shares in DE:BNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
B.R.A.I.N. Biotechnology Research and Information Network Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
B.R.A.I.N. Biotechnology Research and Information Network AG
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.